Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases.
Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Mair MJ, Starzer AM, Forstner H, Rottenmanner B, Aretin MB, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Pfeiler G, Singer C, Weltermann A, Berchtold L, Preusser M.
Bartsch R, et al. Among authors: bergen es.
Neuro Oncol. 2024 Dec 5;26(12):2305-2315. doi: 10.1093/neuonc/noae123.
Neuro Oncol. 2024.
PMID: 38963808
Free PMC article.
Clinical Trial.